您现在位置： -医药产业>>研究报告>>English reports>>English reports>> 浏览医药行业研究报告

Second line drugs for nonsmall-cell lung cancer report

作者：wangchun 来源：本站原创 点击数： 0更新时间：2007-8-31 14:41:16

[关键字]： nonsmall-cell lung cancer,Docetaxel,Gefitinib

讯：

Market report of second line drugs for nonsmall-cell lung cancer (NSCLC)

Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: June 2007
Format: Adobe PDF
Price: US$ 1,200
Contact: Mr. Bian chenghua Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101 Fax: 86-10-68052525
E-mail:bianch@healthoo.comwuhf@healthoo.com

Table of contents

1．Overview of Chinese anticancer market
2．Aanalysis on second line drugs for nonsmall-cell lung cancer
Docetaxel
Gefitinib
Pemetrexed
Appendix: Reatail prices of the three drugs

Tables or figures

1 Sales values of second line drugs for nonsmall-cell lung cancer in sample hospitals from 2005 to 2006
2 Sales amount of second line drugs for nonsmall-cell lung cancer in sample hospitals from 2005 to 2006
3 Sales statistic of Docetaxel with different specifications from 2005 to 2006
4 Detail statistic of Docetaxel in sample hospitals in 2005
5 Detail statistic of Docetaxel in sample hospitals in 2006
6 Detail statistic of Gefitinib in sample hospitals from 2005 to 2006
7 Sales statistic of Pemetrexed in sample hospitals in 2006
8 Reatail prices of the three drugs

Second line drugs for nonsmall-cell lung cancer report 注册后,我们会为你提供报告样本并为您提供更全面的咨询服务 您的姓名 称谓:先生女士 手机号码 电子邮件 单位名称